Key result
Empiric slow-pathway ablation for presumed AVNRT in pediatric patients achieved a 97.4% procedural success rate and a 12.6% follow-up recurrence rate over approximately 46.9 months.
Why the study?
Data are limited regarding empiric slow-pathway ablation in pediatric patients with non-inducible presumed AVNRT during electrophysiological study.
Does empiric slow-pathway ablation prevent tachycardia recurrence in pediatric patients with presumed but uninducible AVNRT?
Cohort (n=79)
Does empiric slow-pathway ablation prevent tachycardia recurrence in pediatric patients with presumed but uninducible AVNRT?
Empiric slow-pathway ablation is a safe and effective strategy with a 97.4% procedural success rate and low documented recurrence in pediatric patients with presumed AVNRT that is uninducible during EPS.
May support empiric ablation in select pediatric presumed AVNRT cases; leaves open need for RCTs to confirm efficacy.
BACKGROUND: In pediatric patients with documented narrow QRS tachycardia that is suggestive of atrioventricular nodal reentrant tachycardia (AVNRT) and not inducible in electrophysiological study (EPS), empiric slowpathway ablation (ESPA) may be considered. There is limited data in children about this topic. METHODS: Seventy-nine patients who underwent cryoablation and/or radiofrequency ablation (RFA) for presumed AVNRT between January 2010 and January 2020, with no inducible tachycardia and no other tachycardia mechanisms during EPS, were included in this study. RESULTS: The age was between 6 and 18 years. All patients had no structural heart disease. Preablation exhibited sustained SP conduction for all patients. In all cases, the ablation end points were prolongation in wenckebach cycle length (WBCL) with loss of cross and/or jump, and/or echo beat. The end points were not achieved in two patients. Overall, the mean basal WBCL increased to 351 ms (240-500 ms) from 301.3 ms (180-420 ms), evident in the non-recurrence group. Nine patients had a transient AV block that improved. We followed the patients without medication for about 46.9 months (8 months to 10 years). Palpitations occurred again in 9 of 77 patients (clinical recurrence rate 9/79 - 11.3%). The documented ECG recurrence rate was 1.2% (1/79). In the non-recurrence group, WBCL prolongation was higher and mean age was lower than in the recurrence group (13.075 vs. 15.33 years). CONCLUSION: In cases with presumed AVNRT, ESPA seems to be a reasonable and safe way. In our study, we found our procedural success rate as 97.4% and follow-up recurrence rate as 12.6% (9+1/79).
No takes yet. Share an insight, caveat, or question.
Duman et al. (2021) conducted a cohort in Presumed atrioventricular nodal reentrant tachycardia (AVNRT) (n=79). Empiric slow-pathway ablation (ESPA) was evaluated on Procedural success. Empiric slow-pathway ablation for presumed AVNRT in pediatric patients achieved a 97.4% procedural success rate and a 12.6% follow-up recurrence rate over approximately 46.9 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: